drugset / Trial / NCT05385900

Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer

NCT05385900

Unknown 57 enrolled Xijing Hospital
NaSingle-groupOpen-labelTreatment

Summary

An exploratory study of pembrolizumab combined with anlotinib and chemotherapy in the perioperative treatment of locally advanced gastric cancer

Timeline

Start
2022-06-30
Primary completion
2023-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral
Subject Oxaliplatin Small molecule
Subject Paclitaxel Small molecule
Subject Penpulimab Monoclonal antibody 200 mg

Indications